stockrowDenali Therapeutics Inc.
DNLI Healthcare Biotechnology
Denali Therapeutics Inc.’s revenue for fiscal 2023 (year ended December 2023) was $330.5 million, up 204.7% from fiscal 2022.
- Revenue
- −94.0%
- EPS
- +150.3%
- Free cash flow
- −11.8%
- Total debt
- −1.89%
Quarter to September 2026, against a year earlier
Follow DNLI
Alert me
Denali Therapeutics Inc. (DNLI) Current ratio
Denali Therapeutics Inc.'s current ratio at the end of the quarter to 30 September 2026 was 6.2×, down 2.9× from fiscal 2025 (9.2×). Over the past ten years it has ranged from 2.4× (fiscal 2021) to 28.9× (fiscal 2017); the current reading is higher than 36% of that period. That is above the Biotechnology industry median of 4.9× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 9.2× | 8.28% |
| FY2024 | 8.5× | (38.02%) |
| FY2023 | 13.6× | 261.87% |
| FY2022 | 3.8× | 58.97% |
| FY2021 | 2.4× | (88.63%) |
| FY2020 | 20.9× | 119.96% |
| FY2019 | 9.5× | (35.34%) |
| FY2018 | 14.7× | (49.29%) |
| FY2017 | 28.9× | 44.73% |
| FY2016 | 20.0× | 108.06% |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 6.2× | (25.78%) |
| Jun 2026 | 8.4× | (9.86%) |
| Mar 2026 | 9.3× | 1.39% |
| Dec 2025 | 9.2× | (6.47%) |
| 34 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| ELVN Enliven Therapeutics, Inc. compare | 64.1× |
| VRDN Viridian Therapeutics, Inc. compare | 14.5× |
| DYN Dyne Therapeutics, Inc. compare | 12.0× |
| IDYA IDEAYA Biosciences, Inc. compare | 9.0× |
| CELC Celcuity, Inc. compare | 8.9× |
| VKTX Viking Therapeutics, Inc. compare | 7.3× |
| DNLI Denali Therapeutics Inc. | 6.2× |
| TLX Telix Pharmaceuticals Limited compare | 2.0× |
| TARS Tarsus Pharmaceuticals, Inc. compare | 2.0× |
| Biotechnology industry median | 4.9× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on DNLI
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- The full statement